Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.00, in-line with the analyst estimate of $1.00. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $52.91 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Sun Communities names Ileana McAlary as general counsel and EVP